Praxis Precision Medicines (PRAX)
NASDAQ:PRAX
Want to see PRAX full AI Analyst Report?
Earnings Data
Report Date
Aug 10, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-3.67Last Year’s EPS
-3.31Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated strong operational and clinical momentum: two NDAs accepted with PDUFA dates, rapid completion of a key EMBOLD study, an impressive 77% placebo‑adjusted seizure reduction in EMBRAVE Part A, multiple upcoming pivotal readouts, and a strengthened balance sheet ($1.4B, +51% vs. year‑end). Management is heavily investing in commercialization and late‑stage development (Q1 operating cash use +62% YoY), which raises short‑term cash burn and execution risk. Regulatory timing, heterogeneous populations in broad DEE, and U.S. pricing dynamics are notable uncertainties but are framed as manageable. On balance, the positive clinical data, regulatory progress, and substantial cash runway outweigh the cost and execution risks.Company Guidance
NDAs Accepted for Two Key Programs with Set PDUFA Dates
The FDA accepted NDAs for ulixacaltamide (Ulixa) and relutrigine with PDUFA dates set (Ulixa: January 29 next year; relutrigine: September 27). Company is ramping commercial efforts for potential U.S. launches within the next ~8 months.
Strong Clinical Milestones and Readouts Ahead
Completed recruitment for the EMBOLD broad DEE study with top-line results expected in Q4 2026. POWER1 readout for lamotrigine expected later this quarter. POWER2 enrollment progressing and expected to finalize this year with a readout early next year.
EMBRAVE Part A: Robust ASO Efficacy Signal
EMBRAVE Part A (elsunersen) in 9 children showed a 77% placebo-adjusted reduction in monthly seizures and demonstrated disease‑modifying components across multiple domains while maintaining a generally safe and well-tolerated profile.
Large Pipeline and Commercial Potential
Company highlights 4 late-stage assets with >$20 billion in peak sales potential; Ulixa alone is estimated to represent over $10 billion in peak sales (company estimate). Relutrigine expansion to broad DEE could target ~200,000 U.S. patients; vormatrigine targets ~3.5 million people with epilepsy in the U.S.
Robust Balance Sheet and Cash Infusion
Cash, cash equivalents, and marketable securities were $1.4 billion as of March 31, 2026, up from $926 million at December 31, 2025 — an increase of approximately $474 million (+51%). The company expects this cash to fund operations into 2028.
Commercial and Manufacturing Preparations Underway
Commercial leadership in place; field force hiring and training planned pre-launch; distribution network established. Ulixa supply includes two independent drug substance manufacturers and inventory planning at commercial scale (company cited 'metric tons' scale for Ulixa).
Strong Scientific Engagement and External Validation
Company presented 15 scientific presentations at the AAN meeting, including a plenary that received an Abstract of Distinction and Movement Disorder Awards. Large physician (2,300+) and patient (1,300+) observational studies validated Ulixa's profile (efficacy, breadth of benefits, tolerability).
Increased Investment in Commercialization and R&D
Operating expenses in Q1 were approximately $106 million, with R&D $78 million (73.6% of Opex) and SG&A $28 million (26.4%), reflecting deliberate investment to support launches and late-stage programs.
PRAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PRAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $338.07 | $333.28 | -1.42% |
Feb 19, 2026 | $328.93 | $331.61 | +0.81% |
Nov 05, 2025 | $171.75 | $164.64 | -4.14% |
Aug 04, 2025 | $54.09 | $51.09 | -5.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Praxis Precision Medicines (PRAX) report earnings?
Praxis Precision Medicines (PRAX) is schdueled to report earning on Aug 10, 2026, Before Open (Confirmed).
What is Praxis Precision Medicines (PRAX) earnings time?
Praxis Precision Medicines (PRAX) earnings time is at Aug 10, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PRAX EPS forecast?
PRAX EPS forecast for the fiscal quarter 2026 (Q2) is -3.67.